- Home
- VRTX
as 03-31-2025 2:13pm EST
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 104.8B | IPO Year: | 1991 |
| Target Price: | $505.61 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $377.85 - $519.88 | Next Earning Date: | 05-05-2025 |
| Revenue: | $11,020,100,000 | Revenue Growth: | 11.66% |
| Revenue Growth (this year): | 10.64% | Revenue Growth (next year): | 9.01% |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Mar 13 '25 | Sell | $510.00 | 3,231 | $1,647,810.00 | 23,281 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Mar 10 '25 | Sell | $499.99 | 3,242 | $1,620,967.58 | 51,239 | |
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Mar 10 '25 | Sell | $500.00 | 3,231 | $1,615,500.00 | 23,281 | |
| WAGNER CHARLES F JR | VRTX | EVP & Chief Financial Officer | Mar 10 '25 | Sell | $500.00 | 3,298 | $1,649,000.00 | 51,671 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Mar 4 '25 | Sell | $485.49 | 4,058 | $1,970,118.42 | 51,239 | |
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Mar 3 '25 | Sell | $490.00 | 3,231 | $1,583,190.00 | 23,281 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 26 '25 | Sell | $475.34 | 530 | $251,930.20 | 51,239 | |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Feb 26 '25 | Sell | $475.34 | 2,650 | $1,259,651.00 | 19,352 | |
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Feb 26 '25 | Sell | $480.00 | 1,272 | $610,560.00 | 23,281 | |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Feb 24 '25 | Sell | $480.95 | 884 | $425,159.80 | 9,086 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Insider Monkey
5 hours ago
Jim Cramer on Vertex Pharmaceuticals (VRTX): “Revolutionary Pain Drug on the Horizon!”
Pharmaceutical Technology
7 hours ago
Vertex halts development of diabetes cell therapy after trial failure
MT Newswires
7 hours ago
Vertex Pharmaceuticals Ends VX-264 Study in Diabetes After Failing to Meet Efficacy Endpoint
Simply Wall St.
2 days ago
Vertex Pharmaceuticals (NasdaqGS:VRTX) Advances Diabetes Portfolio Despite 2% Decline in Share Price
Insider Monkey
3 days ago
Is Vertex Pharmaceuticals (VRTX) The Most Expensive Stock Insiders Are Dumping In March?
Zacks
3 days ago
Vertex Pharmaceuticals (VRTX) Stock Moves -1.96%: What You Should Know
Business Wire
3 days ago
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
Motley Fool
3 days ago
Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession
Compare VRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.